RhumbLine Advisers
RXRX icon

RhumbLine Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

RhumbLine Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39M Buy
651,214
+47,455
+8% +$158K ﹤0.01% 1854
2026
Q1 		$1.85M Buy
603,759
+96,531
+19% +$373K ﹤0.01% 1898
2025
Q4 		$2.07M Sell
507,228
-13,557
-3% -$67.1K ﹤0.01% 1864
2025
Q3 		$2.54M Buy
520,785
+3,530
+0.7% +$18.5K ﹤0.01% 1772
2025
Q2 		$2.62M Buy
517,255
+158,080
+44% +$777K ﹤0.01% 1742
2025
Q1 		$1.9M Buy
359,175
+25,143
+8% +$183K ﹤0.01% 1830
2024
Q4 		$2.26M Buy
334,032
+23,564
+8% +$158K ﹤0.01% 1828
2024
Q3 		$2.05M Buy
310,468
+29,120
+10% +$209K ﹤0.01% 1900
2024
Q2 		$2.11M Buy
281,348
+54,576
+24% +$476K ﹤0.01% 1856
2024
Q1 		$2.26M Buy
226,772
+7,705
+4% +$85.8K ﹤0.01% 1852
2023
Q4 		$2.16M Sell
219,067
-2,134
-1% -$15.2K ﹤0.01% 1860
2023
Q3 		$1.69M Sell
221,201
-36,774
-14% -$367K ﹤0.01% 1938
2023
Q2 		$1.93M Buy
257,975
+48,097
+23% +$337K ﹤0.01% 1920
2023
Q1 		$1.4M Buy
209,878
+4,291
+2% +$34K ﹤0.01% 1989
2022
Q4 		$1.58M Buy
205,587
+863
+0.4% +$8.46K ﹤0.01% 1909
2022
Q3 		$2.18M Buy
204,724
+16,058
+9% +$163K ﹤0.01% 1710
2022
Q2 		$1.54M Buy
188,666
+64,774
+52% +$433K ﹤0.01% 1909
2022
Q1 		$887K Buy
123,892
+4,818
+4% +$51.2K ﹤0.01% 2173
2021
Q4 		$2.04M Buy
119,074
+93,790
+371% +$1.76M ﹤0.01% 1871
2021
Q3 		$582K Buy
25,284
+4,466
+21% +$127K ﹤0.01% 2479
2021
Q2 		$760K Buy
+20,818
New +$616K ﹤0.01% 2367

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers's RXRX Position: Q2 2026 in Review

RhumbLine Advisers increased its Recursion Pharmaceuticals (RXRX) stake by 7.9% in Q2 2026, buying an estimated $158K and bringing the position to 651,214 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1854.

RhumbLine Advisers first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $2.62M in Q2 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • RhumbLine Advisers held 651,214 shares of Recursion Pharmaceuticals worth $2.39M as of Q2 2026.
  • RhumbLine Advisers bought 47,455 Recursion Pharmaceuticals shares in Q2 2026, an estimated $158K.
  • Recursion Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1854 holding.
  • RhumbLine Advisers first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • RhumbLine Advisers's Recursion Pharmaceuticals position peaked at $2.62M in Q2 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.